Startup details



ENDOBIOS┬« was founded in September 2018 after groundbreaking datasets showing that our drug candidate, a new natural compound derived from a marine fungus and currently 

in preclinical trials, could be potentially used against multiple neuropathies: a) Initially detecting in vivo antiepileptic activity (no toxicity or signs of sedation), b) our drug candidate showed later activity in an ex vivo neuropathic pain model; c) we then discovered the unprecedented Mode of Action (MOA). Further, ENDOBIOS® is developing a proprietary screening method for the specific induction of novel neuropathic agents from environmental microbial sources.